Displaying 1 - 20 of 2206
Omnicom Group/The Interpublic Group of Co.
The Federal Trade Commission took action to resolve antitrust concerns related to Omnicom Group Inc.’s $13.5 billion acquisition of The Interpublic Group of Companies, Inc. (IPG).
The FTC accepted a proposed consent order that will prevent potential anticompetitive coordination by Omnicom, a global advertising agency that facilitates media buying by representing advertisers in negotiations with media publishers over conditions such as pricing, ad placement, and sponsorships, as well as helping execute advertisers’ ad campaigns.
FTC Prevents Anticompetitive Coordination in Global Advertising Merger
GTCR BC Holdings, LLC and Surmodics, Inc., In the Matter of
The Federal Trade Commission issued an administrative complaint to challenge GTCR BC Holdings, LLC’s acquisition of Surmodics, Inc., alleging that the deal, which seeks to combine the two largest manufacturers of critical medical device coatings, is anticompetitive. The FTC charges that private equity firm GTCR’s proposed acquisition of Surmodics would create a combined company controlling more than 50% of the market for outsourced hydrophilic coatings. These coatings are often used by medical device manufacturers and are applied to lifesaving medical devices such as catheters and guidewires.
The Federal Trade Commission filed an amended complaint adding the states of Illinois and Minnesota as co-plaintiffs in the Commission’s lawsuit challenging GTCR BC Holdings, LLC’s (GTCR) acquisition of Surmodics, Inc. (Surmodics). The amended complaint also adds GTCR, LLC as an additional defendant in the case.
FTC and DOJ to Host Listening Sessions on Lowering Americans’ Drug Prices Through Competition
Deere & Company, FTC v.
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
FTC to Require Synopsys and Ansys to Divest Assets to Proceed with Merger
Synopsys, Inc. and ANSYS, Inc., In the Matter of
The Federal Trade Commission will require Synopsys, Inc. and Ansys, Inc., under a proposed consent order, to divest certain assets to resolve antitrust concerns surrounding their $35 billion merger. The proposed consent order settles FTC allegations (link to complaint) that Synopsys’s acquisition of Ansys is anticompetitive across three markets – optical software tools, photonic software tools for designing and simulating photonic devices, and RTL power consumption analysis tools.
FTC Dismisses Lawsuit Against PepsiCo
Statement of Commissioner Mark R. Meador In the Matter of Non-Alcoholic Beverages Price Discrimination Investigation
Statement of Chairman Andrew N. Ferguson Joined by Commissioner Melissa Holyoak In the Matter of Non-Alcoholic Beverages Price Discrimination Investigation
FTC and DOJ File Statement of Interest in Energy Collusion Case Against BlackRock, State Street, and Vanguard
FTC Renews Challenge of More Than 200 Improper Patent Listings
FTC Approves Final Order with Welsh Carson
Welsh, Carson, Anderson & Stowe, In the Matter of
FTC Chairman Testifies Before House Appropriations Committee on Agency’s Budget
XCL Resources Holdings, LLC et al, USA v.
The Federal Trade Commission announced that crude oil producers XCL Resources Holdings, LLC (XCL), Verdun Oil Company II LLC (Verdun), and EP Energy LLC (EP) will pay a record $5.6 million civil penalty to settle allegations they engaged in illegal pre-merger coordination, known as gun jumping, in violation of the Hart-Scott-Rodino Act (HSR Act).